Condition Spotlight: Prostate Cancer

Urologist consultation for male patient, prostate, cancer, prostatitis, oncology, urology, photo

HRR Testing & PARPi Underutilized in Patients With Metastatic Prostate Cancer

Only half of patients with metastatic castration-resistant prostate cancer were tested for HRR mutations, and PARP inhibitors were underused.

READ THE STORY

Apr 11, 2024

Baseline Bone Pain Associated With Worse Survival in Metastatic Prostate Cancer

Men with metastatic hormone-sensitive prostate cancer who experience baseline bone pain have worse survival outcomes despite treatment intensification.

Apr 3, 2024

Multiracial crowd, community, race, racial, racial disparity, people, Vector illustration

Racial Disparities in Healthcare Perception Among Patients With Prostate Cancer

Various sessions at the 2024 ASCO Genitourinary Cancers Symposium reviewed health care discrimination and disparities among patients with prostate cancer.

Mar 29, 2024

PW QUIZ

Bone-Protective Agents Beneficial in Patients Receiving Radium-223 for Metastatic Prostate Cancer

Researchers emphasized the importance of bone-protective agents in patients treated for metastatic castration-resistant prostate cancer.

Mar 29, 2024

Senior man holding a blue prostate cancer awareness ribbon, urology, oncology, photo

Predicting Survival in Newly Diagnosed Metastatic Prostate Cancer: The Value of PSMA PET Imaging & AI

Researchers found correlations between PSMA PET total tumor burden and survival in patients with high-volume metastatic hormone-sensitive prostate cancer.

Mar 29, 2024

Doctor with stethoscope question mark. medical advice health care confusion quiz survey poll

Think You Know the Latest in Prostate Cancer Research?

Test your knowledge of the latest prostate cancer studies and news—take this quiz!

Dec 6, 2023

RECIP 1.0’s Prognostic Value in Biochemically Recurrent Prostate Cancer Imaging

The following is a summary of "Prognostic utility of RECIP 1.0 with manual and AI-based...

Nov 14, 2023

EXPLORE MORE

Mortality Risk Comparable With Continuous Versus Intermittent ADT for Prostate Cancer

Nov 14, 2023

An analysis of 12 clinical trials shows no difference in mortality risk with continuous versus intermittent androgen deprivation therapy for prostate cancer.

In Clinical Trial Setting, Survival Is Similar for Black & White Patients With Prostate Cancer

Nov 11, 2023

Both Black and White patients with metastatic castration-sensitive prostate cancer (mCSPC) showed similar progression-free survival and overall survival in a clinical trial setting.